- Home
- NGNE vs FDMT Comparison
NGNE vs FDMT Comparison
Compare NGNE & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- FDMT
- Stock Information
- Founded
- NGNE 2003
- FDMT 2013
- Country
- NGNE United States
- FDMT United States
- Employees
- NGNE N/A
- FDMT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- FDMT Health Care
- Exchange
- NGNE Nasdaq
- FDMT Nasdaq
- Market Cap
- NGNE 471.1M
- FDMT 420.7M
- IPO Year
- NGNE N/A
- FDMT 2020
- Fundamental
- Price
- NGNE $15.59
- FDMT $7.99
- Analyst Decision
- NGNE Strong Buy
- FDMT Strong Buy
- Analyst Count
- NGNE 6
- FDMT 9
- Target Price
- NGNE $60.80
- FDMT $46.75
- AVG Volume (30 Days)
- NGNE 539.5K
- FDMT 769.3K
- Earning Date
- NGNE 11-18-2024
- FDMT 11-13-2024
- Dividend Yield
- NGNE N/A
- FDMT N/A
- EPS Growth
- NGNE N/A
- FDMT N/A
- EPS
- NGNE N/A
- FDMT N/A
- Revenue
- NGNE $925,000.00
- FDMT $17,000.00
- Revenue This Year
- NGNE N/A
- FDMT N/A
- Revenue Next Year
- NGNE N/A
- FDMT $57.85
- P/E Ratio
- NGNE N/A
- FDMT N/A
- Revenue Growth
- NGNE N/A
- FDMT N/A
- 52 Week Low
- NGNE $12.49
- FDMT $7.32
- 52 Week High
- NGNE $74.49
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- NGNE 26.51
- FDMT 40.80
- Support Level
- NGNE $35.60
- FDMT $8.04
- Resistance Level
- NGNE $43.24
- FDMT $8.96
- Average True Range (ATR)
- NGNE 6.30
- FDMT 0.60
- MACD
- NGNE -5.15
- FDMT 0.16
- Stochastic Oscillator
- NGNE 1.85
- FDMT 36.02
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.